Román UG

Idioma: Español
Referencias bibliográficas: 28
Paginas: 285-290
Archivo PDF: 153.47 Kb.

RESUMEN

Para la detección de ADN de los tipos virales de riesgo en el desarrollo de Cáncer de Cérvix Uterino, existen varios métodos utilizados tanto en investigación como en práctica clínica. La valoración de la utilidad de estos métodos es fundamental para el médico costarricense, tanto para la crítica adecuada de las investigaciones, como la interpretación de los resultados en la clínica. La presente revisión pretende informar sobre estos métodos y en especial evaluar la efectividad del método de Captura Híbrida de ADN de Virus de Papiloma Humano HC 2, en función de su sensibilidad y su especificidad, y en comparación con los otros métodos. Se concluye que el método HC 2 tiene gran utilidad en la población femenina con diagnóstico de ASCUS para su seguimiento, y en detección se debe tener en cuenta factores como el carácter pasajero de algunas infecciones por VPH y las reacciones cruzadas que pueden ocurrir con subtipos virales de bajo riesgo. Además es especialmente útil en mujeres de 30 años o más. En absoluto queda claro que la prueba no sustituye la Citología Exfoliativa para tinción de Papanicolau (PAP), pero debido a su alta sensibilidad, puede aportar datos de utilidad para definir el seguimiento. Pero la baja especificidad alerta sobre la posibilidad de incurrir en estudios diagnósticos y afección psicológica innecesarias; lo importante es la interpretación de la prueba dentro del contexto clínico de cada paciente.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Alberts. Molecular Biology of The Cell. III. Methods. 8. Manipulating Proteins, DNA and RNA. www.ncbi.com.

2. Arbyn, Marc et al. Virologic Versus Cytologic Triage of Women With Equivocal Pap Smears: A Meta-analysis of the Accuracy To Detect High-Grade Intraepithelial Neoplasia. Journal of the National Cancer Institute. Vol 96, No. 4, February 18, 2004.

3. Ault, Kevin A. Clinical Study: Epidemiology and Natural History of Human Papillomavirus Infections in the Female Genital Tract. Infectious Disease in Obstetrics and Gynecology. 2006, article ID 40470, Pages 1-5.

4. Beerens, E., et al. Human papillomavirus DNA detection in women with primary abnormal cytology of the cervix: prevalence and distribution of HPV genotypes. Cytopathology. 2005, 16, 199-205.

5. Birner, Peter M.D. et al. Signal-Amplified Colorimetric in situ Hybridization for Assessment of Human Papillomavirus Infection in Cervical Lesions. Mod Pathol 2001; 14 (7): 702-709.

6. Castle, Phillip E. et al. Restricted Cross- Reactivity of Hybrid Capture 2 with Nononcogenic Human Papillomavirus Types. Cancer Epidemiology, Biomarkers and Prevention. Vol 11, 1394-1399. November 2002.

7. Cavuslu, Saban et al. Analytic Sensitivities of Hybrid-Capture, consensus and Type-Specific Polymerase Chain Reactions for the Detection of Human Papillomavirus Type 16 DNA. Journal of Medical Virology 49: 319-324 (1996).

8. Cremoux, Patricia et al. Efficiency of the Hybrid Capture 2 HPV DNA Test in Cervical Cancer Screening. American Journal of Clinical Pathology. Abstract*.

9. Godfroid, Edmond et al. Detection and identification of human papilloma viral DNA, types 16, 18 and 33, by a combination of polymerase chain reaction and colorimetric solid phase capture hybridisation assay. Journal of Virological Medicine. Vol 74, Issue 1, November 1998, pp 69-81. Abstract.*

10. Her-Juing, Howard, et al. Reflex high-risk human papilloma virus DNA test is useful in the triage of women with atypical squamous cells cannot exclude high grade squamous intraepithelial lesion. Diagnostic Cytopathology. Vol 34, Issue 10, pp 707-710. 2006. Abstract*

11. Hesselink, Albertus T. et al. Comparison of Hybrid Capture 2 with in situ Hybridization for the Detection of High-Risk Human Papillomavirus in Liquid-Based Cervical Samples. Cancer Cytophatology. Vol 102, No. 1, February 25. 2004.

12. Hudelist, Gernot. Et al. Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecologic Oncology. 92 (2004) 873-880.

13. Ikenberg, H. et al. Semiquantitative analysis of human papillomavirus DNA in cervical intraepithelial neoplasia by a differential polymerase chain reaction. Journal of Obstetrics and Gynaecology. 1997. vol 17. No. 2. 176-179.

14. Kühler, Christina, et al. Polymerase chain reaction-assisted papillomavirus detection in cervicovaginal smears: stratification by clinical cytology reports. Virchows Archives. 1994. 425; 157-163.

15. de Lang, Anna; et al. Significance of HPV tests on women with cervical smears showing ASCUS. Acta Obstetricia et Gynecologica Scandinavica. 2005, Vol 84; 1001-1005.

16. Lee, G-Y, et al. Human papillomavirus (HPV) genotyping by HPV DNA chip in cervical cancer and precancerous lesions. Int J Gynecol Cancer. 2005. 15, 81-87.

17. Levy, Angelique W. et al. Atypical Squamous Cells of Undetermined Significance in Liquid-Based Cytologic Specimens: Results of Reflex Human Papillomavirus Testing and Histologic Follow-Up in Routine Practice with comparison of Interpretive and Probabilistic Reporting Methods. Cancer Cytopathology. Vol 99. No. 4, August 25, 2003.

18. Lorinez, Attila T. Screening for cervical Cancer: New alternatives and research. Salud Pública de México. 2003. Vol 45, suplemento 3. pp s376-s387.

19. Mc Nicol, Anne and Ferquharson, Maura A. Review Article: In Situ hybridization and its diagnostic applications in pathology. The Journal of Pathology. Vol 182, Issue 3, pp 250-261.

20. Nasar Qureshi, M.D. et al. Role of HPV DNA testing in predicting cervical intraepithelial lesions: Comparison of HC HPV and ISH HPV. Diagnostic Cytopathology. Vol 29, Issue 3, pages 149-155. Abstract.*

21. Nieminen, Pekka et al. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer. Interntaional Journal of Obstetrics and Gynaecology. August 2004. Vol 111, pp 842-848.

22. Ogura, Kanako, et al. Human papillomavirus localization in cervical adenocarcinoma and adenosquamous carcinoma using in situ polymerase chain reaction: Review of the literature of human papillomavirus detection in these carcinomas. Pathology International. 2006. 56; 301-308.

23. Pilch, H. et al. The presence of HPV DNA in cervical cancer: Correlation with clinico-pathologic parmeters and prognostic significance: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University. Int J Gynaecol Cancer. 2001. 11, 39-48.

24. Pisal, Narendra et al. Triage by HPV DNA testing: is it useful in women with persistent minor smear abnormalities?. Acta Obstet Gynecol Scand 2003; 82, 575-577.

25. Seme, Katia, et al. Resolving repetedly borderline results of Hybrid Capture “ HPV DNA Test using Polymerase Chain reaction and genotyping. Journal of Virological Methods. Vol 134, Issues 1-2, June 2006. Pp 252-256. Abstract.

26. Shiunn, Jean et al. Correlation of human papillomavirus 16 and 18 with cervical neoplasia in histological typing and clinical stage in Taiwan: An in situ polymerase chain reaction approach. Journal of Surgical Oncology. Vol 78, Issue 2, pp 101-108. 2001.

27. Skydberg, Barbro et al. Human Papillomavirus Infection, Centrosome Aberration, and Genetic Stability in Cervical Lesions. Mod Pathol. 2001. 14 (4): 279-284.

28. Söderlund-Strand, Anna. Comparison between the Hybrid Capture II Test and PCR- Based Human Papillomavirus Detection Method for Diagnosis and Posttreatment Follow_U of Cervical Intraepithelial Neoplasia. Journal of Clinical Microbiology. July 2005. p 3260-3266.